PE20141685A1 - Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios - Google Patents
Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatoriosInfo
- Publication number
- PE20141685A1 PE20141685A1 PE2014000988A PE2014000988A PE20141685A1 PE 20141685 A1 PE20141685 A1 PE 20141685A1 PE 2014000988 A PE2014000988 A PE 2014000988A PE 2014000988 A PE2014000988 A PE 2014000988A PE 20141685 A1 PE20141685 A1 PE 20141685A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- pharmaceutical compositions
- inflammatory disorders
- alkyl
- dihydropyrimidinoisoquinolinones
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA IA, DONDE: R1 ES H, HALO; L1 ESTA AUSENTE O ES -O-, -S-, ENTRE OTROS; G ES R2, -W-L2-R2, O -W-L3-R3; W ES ALQUILENO C1-C4, ALQUENILENO 2C-4C ENTRE OTROS; L2 ESTA AUSENTE O ES -O-; R2 ES H, ALQUILO 1C-8C, ENTRE OTROS; L3 ES NR4B; R3 ES ALQUILO 1C-4C SUSTITUIDO; HETEROARILO O ARILO; R4B ES H, ALQUILO 1C-4C O CICLOALQUILO 3C-7C. SON COMPUESTOS PREFERIDOS: 9-ALILOXI-2-([1,4] DIOXAN-2-ILMETOXI)-6,7-DIHIDRO-PIRIMIDO[6,1-A]ISOQUINOLIN-4-ONA; 2-([1,4]DIOXAN-2-ILMETOXI)-9-PIRIDIN-4-IL-6,7-DIHIDRO-PIRIMIDO[6,1-A]ISOQUINOLIN-4-ONA; ENTRE OTROS. DICHO COMPUESTO ES ANTAGONISTA DEL GPR84 (PROBABLE RECEPTOR ACOPLADO A PROTEINA G 84). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN METODO PARA SU OBTENCION, SIENDO UTIL EN EL TRATAMIENTO DE AFECCIONES INFLAMATORIAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578979P | 2011-12-22 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141685A1 true PE20141685A1 (es) | 2014-11-25 |
Family
ID=47520068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000988A PE20141685A1 (es) | 2011-12-22 | 2012-12-20 | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US8927543B2 (es) |
| EP (3) | EP4019519A1 (es) |
| JP (1) | JP6062453B2 (es) |
| KR (1) | KR102012268B1 (es) |
| CN (1) | CN103998448B (es) |
| AR (1) | AR089284A1 (es) |
| AU (1) | AU2012357067B2 (es) |
| BR (1) | BR112014015142B1 (es) |
| CA (1) | CA2859578C (es) |
| CL (1) | CL2014001664A1 (es) |
| CO (1) | CO7010835A2 (es) |
| CR (1) | CR20140305A (es) |
| CY (2) | CY1119434T1 (es) |
| DK (2) | DK3378862T3 (es) |
| EA (1) | EA023826B1 (es) |
| ES (2) | ES2643379T3 (es) |
| HR (2) | HRP20171404T1 (es) |
| HU (1) | HUE12812237T4 (es) |
| IL (2) | IL233212B (es) |
| IN (1) | IN2014MN01033A (es) |
| LT (2) | LT2794604T (es) |
| MX (1) | MX351681B (es) |
| NI (1) | NI201400060A (es) |
| PE (1) | PE20141685A1 (es) |
| PH (1) | PH12014501178B1 (es) |
| PL (2) | PL3378862T3 (es) |
| PT (2) | PT3378862T (es) |
| SG (1) | SG11201403169PA (es) |
| SI (2) | SI3378862T1 (es) |
| TW (1) | TWI567073B (es) |
| UA (1) | UA111767C2 (es) |
| UY (1) | UY34545A (es) |
| WO (1) | WO2013092791A1 (es) |
| ZA (1) | ZA201404607B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102072041B1 (ko) | 2011-12-22 | 2020-01-31 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체 |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201319677D0 (en) * | 2013-11-07 | 2013-12-25 | Eth Z Rich | Cyclopropanation |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6918957B2 (ja) * | 2017-03-06 | 2021-08-11 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | Ｇｐｒ８４受容体拮抗剤およびその使用 |
| EP3403649A1 (en) * | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| JP2021502987A (ja) | 2017-11-15 | 2021-02-04 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 線維性疾患の治療における使用のための化合物及びその医薬組成物 |
| US20230112499A1 (en) | 2019-12-19 | 2023-04-13 | Bayer Aktiengesellschaft | Furoindazole derivatives |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| EP4251160A1 (en) | 2020-11-24 | 2023-10-04 | Galapagos N.V. | Compound for use in and methods of treatment of fibrotic diseases |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CA3211437A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| WO2022229061A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2022263676A1 (en) | 2021-06-18 | 2022-12-22 | University Of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| US20240287064A1 (en) * | 2021-06-21 | 2024-08-29 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Tricyclic compound used as gpr84 antagonist |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| WO2024140969A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
| AU2024257923A1 (en) * | 2023-04-17 | 2025-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Method for detecting innate immune action in vivo using gpr84-pet |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
| ATE311884T1 (de) * | 1997-07-12 | 2005-12-15 | Cancer Rec Tech Ltd | Cyclin-abhängige-kinase inhibierende purinderivate |
| MXPA01009847A (es) * | 1999-03-31 | 2003-06-24 | Vernalis Ltd | Derivados de perimido (6, 1 - a) isoquinolin -4- ona. |
| EP1641766A2 (en) * | 2003-07-08 | 2006-04-05 | Smithkline Beecham Corporation | Novel chemical compounds |
| WO2005050225A2 (en) | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| EP1929310A2 (en) | 2005-09-02 | 2008-06-11 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| MX2011001196A (es) | 2008-07-31 | 2011-05-30 | Genentech Inc | Compuestos de pirimidina, composiciones y metodos de uso. |
| JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| SG11201403266RA (en) | 2011-12-22 | 2014-07-30 | Connexios Life Sciences Pvt Ltd | Derivatives of aza adamantane and uses thereof |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| US9453014B2 (en) | 2011-12-22 | 2016-09-27 | Connexios Life Sciences Pvt. Ltd. | Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof |
| IN2014CN04174A (es) | 2011-12-22 | 2015-09-04 | Novartis Ag | |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
-
2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko not_active Expired - Fee Related
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en not_active Ceased
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt not_active IP Right Cessation
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en not_active Withdrawn
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh not_active IP Right Cessation
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh active Active
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en not_active Ceased
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja not_active Expired - Fee Related
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
-
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178B1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
-
2015
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
-
2017
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
-
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
-
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100292T patent/CY1125167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141685A1 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| EA201101026A1 (ru) | Ингибиторы бета-секретазы | |
| CY1119499T1 (el) | Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2 | |
| MX387702B (es) | Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4. | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| PE20142340A1 (es) | Inhibidores de bromodominios | |
| EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| EA201390723A1 (ru) | Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep | |
| CO6700831A2 (es) | Derivados de pirazina como bloqueadores de enac | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| EA201101621A1 (ru) | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы | |
| MX373079B (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago. | |
| EA201400822A1 (ru) | Производные гетероциклических амидов в качестве антагонистов p2xрецептора | |
| EA201101301A1 (ru) | Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh | |
| PE20142244A1 (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina | |
| UY33824A (es) | ?moduladores del receptor del glucagón?. | |
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. | |
| UA107702C2 (xx) | Похідні бензаміду |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |